Hyper Corporation Inc. (KOSDAQ:065650)

Market Cap	28.68B
Revenue (ttm)	64.95B
Net Income (ttm)	-51.23B
Shares Out	13.31M
EPS (ttm)	-4,040.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,279
Average Volume	127,373
Open	2,185.00
Previous Close	2,160.00
Day's Range	2,010.00 - 2,250.00
52-Week Range	1,424.00 - 11,592.00
Beta	1.58
RSI	35.39
Earnings Date	Nov 14, 2025

About Hyper Corporation

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and w...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 1997
• Employees: 44
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065650

Financial Performance

In 2024, Hyper Corporation's revenue was 58.46 billion, an increase of 36.33% compared to the previous year's 42.88 billion. Losses were -80.36 billion, 3999.0% more than in 2023.